Progress of induced pluripotent stem cell (iPSC)-derived renal organoids in clinical application DOI Creative Commons
Ning Na, Zhiting Liu, Xinyu Li

et al.

Kidney Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 10

Published: Nov. 11, 2024

Background: Kidney disease has become a growing public health problem worldwide, and there is an urgent need to develop reliable models for investigating novel effective treatment strategies. In recent years, kidney organoids, as different from traditional two-dimensional cells model animals, have attracted more attention. Current advances allowed the generation of organoids directed differentiation induced pluripotent stem (iPSCs), which possess similar characteristics embryonic cells, but bypass ethical constraints wide range sources. Summary: Herein, methods generating renal iPSCs, applications iPSC-derived in modeling, drug effectiveness detection, regenerative medicine well challenges were reviewed. Key Messages: can be used diseases are great studying injury toxicity. Many efforts needed finally apply into clinical application.

Language: Английский

Human kidney organoids for modeling the development of different diseases DOI
Elena Ceccotti,

Armina Semnani,

Benedetta Bussolati

et al.

Current topics in developmental biology/Current Topics in Developmental Biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Advances and Challenges in Modeling Autosomal Dominant Polycystic Kidney Disease: A Focus on Kidney Organoids DOI Creative Commons
Jinglan Gu, Fei Liu, Lu Li

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 523 - 523

Published: Feb. 19, 2025

Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent hereditary disorder characterized by distinct phenotypic variability that has posed challenges for advancing in-depth research. Recent advancements in organoid construction technologies have enabled researchers to simulate development and create simplified vitro experimental environments, allowing more direct observation of how genetic mutations drive pathological phenotypes disrupt physiological functions. Emerging technologies, such as microfluidic bioreactor culture systems single-cell transcriptomics, further supported the complex ADPKD organoids, offering robust models exploring mechanisms facilitating drug discovery. Nevertheless, significant remain constructing accurate models. This review will summarize recent advances construction, focusing on limitations current techniques critical issues need be addressed future breakthroughs. New Noteworthy: presents particularly iPSC-derived models, new insights into It focuses limited vascularization maturity, proposing potential solutions through emerging technologies. The ongoing optimization expected enhance understanding breakthroughs targeted therapy development.

Language: Английский

Citations

1
Evolving Value and Validity of Animal Models in Veterinary Therapeutic Research: Impact of Scientific Progress DOI Creative Commons
Marilyn N. Martinez, Jonathan P. Mochel, Pierre‐Louis Toutain

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 107111 - 107111

Published: April 1, 2025

In veterinary medicine, experimental in vivo animal models have long been integral to advancing our understanding of disease mechanisms and assessing the safety efficacy potential therapies. However, value validity these warrants reassessment light emerging scientific evidence, evolving standards welfare, development alternative methodologies. Such a is essential for maintaining ethical practices ensuring that research approaches remain both relevant justifiable, especially as awareness pain, sentience, consciousness deepens. While interspecies extrapolation findings from poses challenges when applied human what about cases where an species serves subject intended patient? Additionally, tools are potentially available replace studies contexts? This commentary explores how may improve efforts meet principles 3R's by integrating vitro silico early investigative process utilizing specialized within target population during clinical trials.

Language: Английский

Citations

0
Progress of induced pluripotent stem cell (iPSC)-derived renal organoids in clinical application DOI Creative Commons
Ning Na, Zhiting Liu, Xinyu Li

et al.

Kidney Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 10

Published: Nov. 11, 2024

Background: Kidney disease has become a growing public health problem worldwide, and there is an urgent need to develop reliable models for investigating novel effective treatment strategies. In recent years, kidney organoids, as different from traditional two-dimensional cells model animals, have attracted more attention. Current advances allowed the generation of organoids directed differentiation induced pluripotent stem (iPSCs), which possess similar characteristics embryonic cells, but bypass ethical constraints wide range sources. Summary: Herein, methods generating renal iPSCs, applications iPSC-derived in modeling, drug effectiveness detection, regenerative medicine well challenges were reviewed. Key Messages: can be used diseases are great studying injury toxicity. Many efforts needed finally apply into clinical application.

Language: Английский

Citations

0